Tweet
Bowling Portfolio Management LLC boosted its position in Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 57.8% during the second quarter, Holdings Channel reports. The institutional investor owned 5,047 shares of the biotechnology company's stock after purchasing an additional 1,849 shares during the quarter. Bowling Portfolio Management LLC's holdings in Ligand Pharmaceuticals were worth $1,046,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Rhumbline Advisers increased its holdings in shares of Ligand Pharmaceuticals by 4.3% during the 2nd quarter. Rhumbline Advisers now owns 53,548 shares of the biotechnology company's stock worth $11,094,000 after acquiring an additional 2,215 shares during the last quarter. Navellier & Associates Inc increased its holdings in shares of Ligand Pharmaceuticals by 8.9% during the 2nd quarter. Navellier & Associates Inc now owns 9,849 shares of the biotechnology company's stock worth $2,040,000 after acquiring an additional 808 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Ligand Pharmaceuticals by 20.4% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,326 shares of the biotechnology company's stock worth $275,000 after acquiring an additional 225 shares during the last quarter. Sei Investments Co. increased its holdings in shares of Ligand Pharmaceuticals by 83.4% during the 2nd quarter. Sei Investments Co. now owns 25,061 shares of the biotechnology company's stock worth $5,193,000 after acquiring an additional 11,395 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Ligand Pharmaceuticals during the 2nd quarter worth approximately $934,000. Get Ligand Pharmaceuticals alerts:
A number of research analysts recently weighed in on the company. Stephens reissued a "buy" rating and set a $248.00 target price on shares of Ligand Pharmaceuticals in a report on Wednesday, August 8th. Roth Capital reissued a "neutral" rating on shares of Ligand Pharmaceuticals in a report on Wednesday, August 8th. They noted that the move was a valuation call. Craig Hallum boosted their target price on Ligand Pharmaceuticals from $230.00 to $260.00 and gave the stock a "buy" rating in a report on Tuesday, August 7th. HC Wainwright reissued a "buy" rating and set a $249.00 target price on shares of Ligand Pharmaceuticals in a report on Tuesday, August 7th. Finally, BidaskClub upgraded Ligand Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Thursday, June 28th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of "Buy" and a consensus target price of $200.67. In related news, Director John L. Lamattina sold 4,000 shares of the business's stock in a transaction on Monday, June 4th. The stock was sold at an average price of $194.51, for a total value of $778,040.00. Following the completion of the sale, the director now directly owns 24,956 shares in the company, valued at approximately $4,854,191.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website . Also, Director John W. Kozarich sold 2,500 shares of the business's stock in a transaction on Monday, July 2nd. The shares were sold at an average price of $207.48, for a total value of $518,700.00. Following the completion of the sale, the director now owns 28,642 shares of the company's stock, valued at $5,942,642.16. The disclosure for this sale can be found here . Insiders own 7.80% of the company's stock.
LGND opened at $239.66 on Friday. The firm has a market capitalization of $5.12 billion, a P/E ratio of 93.25, a PEG ratio of 1.69 and a beta of 0.91. Ligand Pharmaceuticals Inc. has a 1 year low of $123.11 and a 1 year high of $255.38. The company has a quick ratio of 2.32, a current ratio of 2.34 and a debt-to-equity ratio of 0.96.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings results on Monday, August 6th. The biotechnology company reported $2.59 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $2.34 by $0.25. The business had revenue of $90.00 million during the quarter, compared to the consensus estimate of $82.20 million. Ligand Pharmaceuticals had a return on equity of 25.95% and a net margin of 52.10%. The firm's quarterly revenue was up 221.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.67 EPS. research analysts expect that Ligand Pharmaceuticals Inc. will post 5.74 EPS for the current fiscal year.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.
Read More: What does EPS mean?
Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Inc. (NASDAQ:LGND). Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter 